KaydedilenlerDerginizi ekleyin

Dergiler / Molecular Imaging and Radionuclide Therapy / 2018 / Cilt: 27 - Sayı: 3

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma

I-131 mIBG Sintigrafi Curie ve SIOPEN Skorlarının Evre 4 Nöroblastomada Prognostik Değerinin Karşılaştırılması

Saima RİAZ
Humayun BASHİR
Saadiya JAVED KHAN
Abid QAZİ
Sayfa
121–125
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Higher scores predict unfavorable prognosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: I-131 mIBG scan semi-quantitative analysis with modified Curie and the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) scoring systems is helpful in the evaluation of disease extent and has prognostic impact in stage 4 neuroblastoma.
📊
Temel Bulgular & Veri:Methods: Retrospective, cross-sectional analysis of baseline I-131 mIBG scans in 21 patients with stage 4 or 4S neuroblastoma diagnosed between January 2007 and December 2015.
💡
Sonuç & Katkı:Higher scores predict unfavorable prognosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:2007 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: I-131 mIBG scan semi-quantitative analysis with modified Curie and the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) scoring systems is helpful in the evaluation of disease extent and has prognostic impact in stage 4 neuroblastoma. Methods: Retrospective, cross-sectional analysis of baseline I-131 mIBG scans in 21 patients with stage 4 or 4S neuroblastoma diagnosed between January 2007 and December 2015. All scans were assessed for Curie and SIOPEN scores. Distribution of scores was evaluated for risk factors i.e. age at diagnosis (>18 months) and early relapse (within 12 months). A curie score 18 months (n=9) at diagnosis or early relapse (n=9) had higher Curie [mean 5+7.5 standard deviation (SD), p=0.004] and SIOPEN (mean 5.2+10.8 SD, p=0.02) scores. Patients with a Curie score 2 (33%) (p=0.03); 5-year OS=Curie 2 (36%) (p=0.01). SIOPEN: 5-year EFS=SIOPEN 4 (17%) (p=0.002); 5-year OS=SIOPEN 4 (17%) (p=0.04). There was no statistically significant difference between the two scoring systems in terms of survival predictive value (Hazard ratio 2.38, 95% CI: 0.33-16.9, p=0.38). Conclusion: I-131 mIBG Curie and SIOPEN scores have prognostication value in stage 4 neuroblastoma and should be routinely applied. Higher scores predict unfavorable prognosis.

Abstract

Amaç: I-131 mIBG sintigrafinin modifiye Curie ve International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) skorlama sistemleri ile yarı-kantitatif analizi evre 4 nöroblastomda hastalığın yayılımını değerlendirmede yararlıdır ve prognostik etkisi bulunmaktadır. Yöntem: Ocak 2007 ile Aralık 2015 tarihleri arasında, evre 4 veya 4S nöroblastom tanısıyla I-131 mIBG sintigrafi yapılmış 21 hastanın retrospektif, kesitsel analizi yapıldı. Tüm tetkikler Curie ve SIOPEN skoru ile değerlendirildi. Tanı yaşı (>18 ay) ve erken nüks (12 ay içinde) gibi risk faktörlerine göre skor dağılımı değerlendirildi. Tanı anında Curie skoru 18 ay olan hastalar (n=9) veya erken nüks edenlerde (n=9) Curie [ortalama 5+7,5 standart deviasyon (SD), p=0,004] ve SIOPEN (ortalama 5,2+10,8 SD, p=0,02) skorları daha yüksek bulundu. Curie skoru 2 (%33) (p=0,03); 5-yıl GS=Curie 2 (%36) (p=0,01). SIOPEN: 5-yıl HGS=SIOPEN 4 (%17) (p=0,002); 5-yıl GS= SIOPEN 4 (%17) (p=0,04). Her iki skorlama sistemi arasında sağkalım öngörücü değer açısından istatistik olarak anlamlı farklılık saptanmadı (Risk oranı: 2,38, %95 CI: 0,33-16,9, p=0,38). Sonuç: I-131 mIBG Curie ve SIOPEN skorlarının evre 4 nöroblastomda prognostik öngörü değeri vardır ve rutin olarak kullanılmalıdır. Yüksek skorlar daha kötü prognozu göstermektedir.

🔖

Bu Makaleye Atıf Yap

RİAZ, S., BASHİR, H., KHAN, S. J., QAZİ, A. (2018). I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma. Molecular Imaging and Radionuclide Therapy, Cilt: 27 - Sayı: 3, 121–125. https://ajindex.com/articles/295066

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165-1173.
  2. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA; St Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-1071.
  3. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47:561-571.
  4. Kreissman SG, Villablanca JG, Diller L, London WB, Maris JM, Park JR, Reynolds CP, Allmen DV, Cohn SL, Matthay KK. Response and toxicity to a doseintensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children’s Oncology Group (COG A3973) study. J Clin Oncol 2007;25:9505. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334.
  5. Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, Wu JL. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984;27:149155. Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 1995;39(Suppl 4):21-24.
  6. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, Gongora R, Manil L. A new 123I-MIBG whole body scan scoring method: application to the prediction of the response of metastases to induction chemo